Aa
  • Read, Watch, Listen
  • TJI Series
  • Community Action
  • Events
  • Zedi
Follow us and continue the conversation
  • LinkedIn
  • Instagram
  • FaceBook
  • X
  • YouTube
Test yourself with the TJI Quiz!

Adjust size of text

Aa

Follow us and continue the conversation

  • LinkedIn
  • Instagram
  • FaceBook
  • X
  • YouTube

Your saved articles

You haven't saved any articles

What are you looking for?

Original reporting, insightful analysis and diverse views, delivered straight to your inbox

  • LinkedIn
  • Instagram
  • FaceBook
  • X
  • YouTube
Your support fuels our mission to inform, entertain and inspire.

The Jewish Independent is bound by the Standards of Practice of the Australian Press Council. If you believe the Standards may have been breached, you may approach The Jewish Independent or make a complaint to the Australian Press Council in writing at www.presscouncil.org.au. The Council may also be contacted on 1800 025 712.

  • Our Story
  • Contact us
  • Our Team
  • Support us
  • Guidelines
  • Pitch your idea
  • Republishing us
  • Community Action
  • Our Awards
  • LinkedIn
  • Instagram
  • FaceBook
  • X
  • YouTube
Aboriginal FlagTorres Strait Islanders Flag

The Jewish Independent acknowledges Aboriginal and Torres Strait Islander peoples as the Traditional Owners and Custodians of Country throughout Australia. We pay our respects to Elders past and present, and strive to honour their rich history of storytelling in our work and mission.

© The Jewish Independent 2026All Rights Reserved
Website design and development by Your Creative, MelbourneTerms & ConditionsPrivacy Policy
HomeRead, Watch, ListenLifestyle
AnalysisLifestyleWorld

We need to talk about cancer risk 

Family and community communication is essential to ensuring new knowledge about genetic cancer risk translates into early intervention
David Adler
Print this
Tech DNA

Digitally-generated image of DNA (Andriy Onufriyenko/Getty)

Published: 16 November 2026

Last updated: 16 November 2026

New research is revealing the importance of genetic connections in the early identification of cancer. 

 A study published in late October identified inherited cancer-risk variants in approximately one in 10 patients who underwent comprehensive tumour genomic profiling and follow-up genetic testing.  

The research has major implications for family members of cancer patients who may be screened and have cancers identified earlier. 

Genetic testing for inherited cancer risk is particularly relevant to the Jewish community, where approximately one in 40 people of Ashkenazi Jewish ancestry carries a harmful inherited change in BRCA1 or BRCA2, which can increase the risk of several cancers, including breast, ovarian and prostate cancer. 

Not everyone needs genetic testing for cancer, but understanding your family's cancer history can help identify who may be at increased risk, who might benefit from genetic counselling or testing, and who could benefit from earlier or more frequent screening to detect cancer when treatment is more effective. 

Family members who learn that they may carry the same harmful genetic change can seek advice about testing and, where appropriate, earlier or more frequent screening.  

Within Australia's Jewish community, we should encourage conversations about family cancer history

Importantly, inheriting a risk does not mean a person will inevitably develop cancer, but the knowledge of genetic risk may help detect some cancers at a stage when treatment is more effective. 

However, there is a question we should be asking within our community. When one person receives a result that could matter to their family, who helps make sure the information reaches the others? 

Imagine a woman in Melbourne who, following a cancer diagnosis, learns that she carries a harmful inherited genetic change that increases cancer risk. Her doctor explains that her brother in Sydney, her children and other relatives may carry the same change, even though they are currently healthy, and that knowing this could help them seek appropriate testing and earlier cancer screening. 

She wants to tell them, but how does she explain it without causing unnecessary alarm? What if they misunderstand? What if she has little contact with some relatives? At an already difficult time, she is suddenly expected to become the family's messenger and genetics adviser. Even in close families, these conversations can be emotionally difficult, and a medical report is hardly the best tool for starting them. 

This is not just a hypothetical problem. An Australian survey found that around four in five responding clinical genetics services did not routinely contact at-risk relatives themselves. Staffing pressures and privacy concerns were among the barriers.  

Although genetics services can provide counselling and family letters, the responsibility for sharing difficult news often falls on patients. We should not assume that receiving information automatically means a family knows how to use it. 

We can do better. When someone receives a confirmed inherited cancer-risk result with implications for relatives, they should be offered a practical family communication plan. That means a plain-language letter, guidance on which relatives might benefit from counselling, and a follow-up conversation if they need more help. With the patient's consent, and where lawful and appropriate, clinicians could also assist with contacting relatives. 

Although Australia has already recognised the importance of sharing inherited cancer-risk information within families, more needs to be done to ensure patients receive consistent, practical support. I believe Australian health authorities should make family communication assistance a standard, adequately funded part of cancer care, rather than leaving it dependent on where patients receive treatment or the resources available to individual services.  

This approach must also protect privacy and respect every relative's right to decide whether to seek advice or testing. The goal is to help families make informed decisions, not to pressure anyone into genetic testing. 

Our Jewish community also has a role. People can ask their families about cancer history and bring relevant information to their GP, particularly if several relatives have been affected or cancers occurred at younger ages. 

Synagogues, community organisations, and Jewish media can share reliable information and direct people to qualified genetic counselling services, without asking anyone to disclose personal results. We can encourage this conversation without turning anyone's personal medical history into public information. 

Within Australia's Jewish community, we should encourage conversations about family cancer history, seek medical advice when inherited risks are suspected and make sure relatives know where to turn for help. However, families should not have to navigate these challenges alone. 

Our healthcare system must provide the guidance and practical support needed to turn genetic information into opportunities for earlier detection and prevention. After all, when knowledge gained from one person could help protect an entire family, we have a responsibility to make sure that opportunity is not lost. 

You might also like
  • The goring ox: who answers for ‘rogue’ AI?
    Yoni Genende
  • My vision for Palestinian cancer patients
    David Adler
  • Synagogue and Jewish-owned shops damaged in French riots
    Ilan Bloom
logomark.67a07ee3
We believe in the free flow of information

Republish our articles for free, online or in print, by using our Creative Commons licence

You might also like

    Mothin Ali UK Greens
    NewsWorld

    British Greens equate Zionism with racism

    Ruth Eglash 1
    Brazilian presidents
    AnalysisWorld

    Brazilian Jews treated as pawns in presidential election

    Karina Stange Calandrin
    Picture 1
    ReflectionWorld

    A Gazan doctor’s journey of hope

    Deea Okasha 1

About the author

David Adler

David Adler

Professor David Adler is Chief Scientific & Medical Officer of the PATHORA Institute of Pathology & Tissue Medicine. He is a senior pharmaceutical leader in oncology drug development and translational medicine with over 15 years of experience, including a decade in senior leadership at Bayer AG’s Global Oncology Clinical Development organisation. He holds academic appointments at the Hebrew University of Jerusalem, Ben-Gurion University of the Negev, and the University of Bonn.

More from the author

OpinionIsrael

My dream for Palestinian cancer patients